# A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin

Study · id `cardio:ct-nct06589765` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06589765](<https://clinicaltrials.gov/study/NCT06589765>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06589765

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 810 participants.

## Technical summary

Registry record NCT06589765. Randomized; double masking; primary purpose treatment. Start 2024-09-27 (actual); primary completion 2026-05-29 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 810 participants (enrolled count; ClinicalTrials.gov record NCT06589765, source copy `cardio:ctgov-nct06589765-2026-06-30`, retrieved 2026-11-18)
- Started: 2024-09-27 (actual) (ClinicalTrials.gov record NCT06589765, source copy `cardio:ctgov-nct06589765-2026-06-30`, retrieved 2026-11-18)
- Primary completion: 2026-05-29 (actual) (ClinicalTrials.gov record NCT06589765, source copy `cardio:ctgov-nct06589765-2026-06-30`, retrieved 2026-11-18)
- Completion: 2026-05-29 (actual) (ClinicalTrials.gov record NCT06589765, source copy `cardio:ctgov-nct06589765-2026-06-30`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT06589765, source copy `cardio:ctgov-nct06589765-2026-06-30`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06589765-2026-06-30`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study of HRS-7535 Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Metformin
- Condition: Type 2 Diabetes
- Intervention (Drug): HRS-7535 tablet
- Intervention (Drug): dapagliflozin tablet
- Lead sponsor: Shandong Suncadia Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Shandong Suncadia Medicine Co., Ltd. (`cardio:org-shandong-suncadia-medicine-co-ltd`)

## Provenance

Content hash: 6046d4abc3e6c0e9759426fccf28b064270af7c47932418aafb9a900160a1799
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
